RASopathic Skin Eruptions during Vemurafenib Therapy

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Rinderknecht, Jeannine D ^a   Goldinger, Simone M ^a   Rozati, Sima ^a   Kamarashev, Jivko ^a   Kerl, Katrin ^a   French, Lars E ^a   Dummer, Reinhard ^a   Belloni, Benedetta ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CORTICOSTEROID; DACARBAZINE; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; RAS PROTEIN; VEMURAFENIB;

ACANTHOPAPILLOMA; ACANTHOSIS; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; BURNING FEET SYNDROME; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DARIER DISEASE; DERMATITIS; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; DYSKERATOSIS; FEMALE; FOLLICULITIS; GENE MUTATION; GERM LINE; HAIR DISEASE; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; INCIDENCE; KERATOACANTHOMA; MACULOPAPULAR RASH; MALE; MELANOCYTOSIS; MELANOMA; METASTATIC MELANOMA; NAIL DISEASE; OBSERVATIONAL STUDY; ONCOGENE RAS; OUTCOME ASSESSMENT; PALMOPLANTAR KERATODERMA; PAPILLOMA; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIMARY TUMOR; PROSPECTIVE STUDY; PRURITUS; SKIN CARCINOMA; SKIN INFECTION; SKIN MANIFESTATION; TREATMENT DURATION; ULTRAVIOLET A RADIATION; WILD TYPE;

ADULT; AGED; CELL PROLIFERATION; FEMALE; HAIR; HUMANS; INDOLES; KERATINOCYTES; MALE; MELANOCYTES; MIDDLE AGED; NAILS; RAS PROTEINS; SKIN DISEASES; SULFONAMIDES; TIME FACTORS; YOUNG ADULT;

EID: 84875037998     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058721     Document Type: Article

References (29)

1. Schad K, Baumann Conzett K, Zipser M, Enderlin V, Kamarashev J, et al. (2010) Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 16(3): 1058-64.
2. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, et al. (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7): 491-500.
3. Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, et al. (2012) Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 18(1): 263-72.
4. Lacouture ME, (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10): 803-12.
5. Zimmer L, Livingstone E, Hillen U, Domkes S, Becker A, et al. (2012) Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 148(3): 357-61.
6. Zimmer L, Vaubel J, Livingstone E, Schadendorf D. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges (in press).
7. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim P, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315): 596-9.
8. Falchook GS, Long GV, Kutzrock R, Kim KB, Arkenau TH, et al. (2012) Dabrafenib in patients with melanoma, untreated brain metastasis, and other solid tumors: a phase 1 dose-escalation trial. Lancet 379(9829): 1893-901.
9. Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9): 809-19.
10. Cichowski K, Jänne P, (2010) Drug discovery: inhibitors that activate. Nature 464(7287): 358-9.
11. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, et al. (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30(3): 316-21.
12. Robert C, Arnault JP, Mateus C, (2011) RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 23(2): 177-82.
13. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26): 2507-16.
14. Eggermont AM, Robert C, (2011) New drugs in melanoma: It's a whole new world. Eur J Cancer 47(14): 2150-7.
15. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287): 431-5.
16. Dummer R, Rinderknecht J, Goldinger SM, Wagner I, Mitchell L, et al. (2011) An Open-label Pilot Study of Vemurafenib in previously treated metastastic melanoma patients with brain metastasis. ASCO Meeting Abstracts J Clin Oncol 2011, Vol 29, abstract 8548.
17. Dummer R, Rinderknecht J, Goldinger SM, (2012) Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 366(5): 480-1.
18. Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K,et al. Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition. J Clin Oncol (in press).
19. Dalle S, Poulalhon N, Thomas L. (2011) Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 365(15): 1448-9; author reply 1450.
20. Su F, Viros A, Milagre C, Trunzer K, Bollag G, et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366(3): 207-15.
21. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140(2): 209-21.
22. Nazarian R, Shi H, Wang Q, Kong X, Koya RC,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468(7326): 973-7.
23. Weeraratna AT, (2012) RAF around the edges-the paradox of BRAF inhibitors. N Engl J Med 366(3): 271-3.
24. Siegel DH, Mann JA, Krol AL, Rauen KA, (2012) Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development. Br J Dermatol 166(3): 601-7.
25. Siegel DH, McKenzie J, Frieden IJ, Rauen KA, (2011) Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome. Br J Dermatol 164(3): 521-9.
26. Hafner C, Hartmann A, Vogt T, (2007) FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin. J Invest Dermatol 127(7): 1572-3.
27. Boyd KP, Vincent B, Andea A, Conry M, Hughey LC, (2012) Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol 67(6): 1375-1379.
28. Anforth R, Blumetti TC, Mohd Affandi A, Fernandez-Penas P, (2012) Systemic retinoid therapy for chemoprevention of nonmelanoma skin sancer in a patient treated with vemurafenib. J Clin Oncol 30(19): e165-167.
29. Dummer R, Tsao H, Robert C, (2012) How cutaneous eruptions help to understand the mode of action of kinase inhibitors. Br J Dermatol 167(5): 965-967.